PhorMed
Early Stage
Utilizing gene therapy to target cancer and mutated cells
Overview
Raised: $2,450,528
Total Commitments ($USD)
Platform
StartEngine
Start Date
12/06/2019
Close Date
03/25/2022
Min. Goal
$10,000
Max. Goal
$5,000,000
Min. Investment
$250
Security Type
Equity - Common
Series
Pre-Seed
SEC Filing Type
RegCF
Price Per Share
$1.00
Pre-Money Valuation
$39,000,000
Rolling Commitments ($USD)
Status
Funded
Reporting Date
03/31/2022
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$2,917
# of Investors
4,097
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2019
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B2C
Margin
High
Capital Intensity
High
PhorMed, with a pre-money valuation of $39 million, is raising funds on StartEngine.It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells, and develops a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed was founded by McCoy Moretz Richard L. Chang and others. The proceeds of the current crowdfunding round, with a minimum target of $10,000 and a maximum target of $107,000, will be used for the Phase 2 clinical trials of the drug. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study and has generated positive outcomes.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$0 |
$0 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$0 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$0 |
$0 |
|
Short-Term Debt |
$0 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$0 |
$0 |
Financials as of: 12/06/2019
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| PhorMed | 01/31/2024 | Dealmaker Securities | $52,523,767 | - | Equity - Common | Active | RegCF |
| PhorMed | 08/17/2022 | StartEngine | $51,647,023 | $243,864 | Equity - Common | Funded | RegCF |
| PhorMed | 03/25/2022 | StartEngine | $39,000,000 | $2,450,528 | Equity - Common | Funded | RegCF |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.